Innovent Biologics, Inc. (FRA:6IB)

Innovent Biologics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 8, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	16,947	7,456	8,030	6,168	7,955	12,136
Market Cap Growth	133.14%	-7.15%	30.17%	-22.46%	-34.45%	216.45%
Enterprise Value	16,203	6,750	7,395	5,388	6,693	11,531
Last Close Price	9.70	4.36	4.50	3.84	5.10	8.05
PS Ratio	12.48	5.98	10.14	9.98	13.46	25.21
PB Ratio	9.89	4.30	5.02	4.24	5.56	11.04
P/TBV Ratio	10.94	4.40	5.04	4.25	5.57	11.04
P/FCF Ratio	98.49	175.32	-	-	-	-
P/OCF Ratio	78.49	43.78	425.78	-	-	-
EV/Sales Ratio	11.74	5.41	9.34	8.72	11.33	23.96
EV/EBITDA Ratio	106.05	2126.28	-	-	-	-
EV/FCF Ratio	94.16	158.73	-	-	-	-
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14
Debt / EBITDA Ratio	2.54	50.93	-	-	-	-
Debt / FCF Ratio	2.33	8.81	-	-	-	-
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40
Inventory Turnover	2.94	2.69	1.51	1.00	1.19	1.45
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%
Return on Assets (ROA)	2.65%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%
Return on Capital (ROIC)	3.46%	-1.08%	-6.49%	-14.57%	-14.81%	-4.46%
Return on Capital Employed (ROCE)	5.00%	-1.60%	-9.70%	-22.20%	-20.50%	-5.40%
Earnings Yield	0.79%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%
FCF Yield	1.02%	0.57%	-1.54%	-6.19%	-5.38%	-0.82%
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.